Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. has established a Gastrointestinal Clinical Advisory Board, including esteemed GI experts, to guide the development of its EP-104GI drug for eosinophilic esophagitis (EoE), which is currently undergoing Phase 1b/2a clinical trials. The company’s proprietary DiffuSphere™ technology aims to improve drug delivery, potentially benefiting patients with EoE—a rare and underserved condition. The advisory group will assist Eupraxia in advancing its clinical program and exploring further applications for its technology.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
